Keywords: aspreva/roche, cellcept, cuts, risk, kidney, damage, liver
Aspreva/Roche
Article | 15 October 2007
In a study of 500 liver transplant patients, USA-based Aspreva and Swiss drug major Roche's co-developed oral immunosuppressant CellCept (mycophenolate motefil) ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Negative US patent ruling for Novo Nordisk on Prandin
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Daiichi Sankyo files for Japanese approval of Prasugrel
